Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
An Access Newswire-linked piece carried by Yahoo Finance highlights heart disease and certain cancers as “silent risks” for many men and describes how CVS Health says it helps make screenings easier to access.
THE APEX TIMES
THE APEX TIMES
A recent Yahoo Finance analysis centered on Eli Lilly’s position in the GLP-1 drug class and used a hypothetical $5,000 investment to illustrate what future gains could look like, while offering no company guidance or new clinical/regulatory updates.
THE APEX TIMES
The companies announced a commercialization agreement covering Verzenios (abemaciclib) in Mainland China, with terms and operational details not fully laid out in the published announcement.
THE APEX TIMES
Eli Lilly (LLY) settled at $1.00, up 1.81% from the previous close, according to Yahoo Finance market coverage.
THE APEX TIMES
Moderna’s stock rose sharply following a pipeline update presented as part of its Science Day programming, with at least one Wall Street firm arguing the company’s prospects remain underappreciated.
THE APEX TIMES
A market-focused note is prompting a simple question for UnitedHealth Group shareholders: is the stock a good bet to hold into the company’s upcoming second-quarter results release, expected in the coming weeks, or wait for the numbers?
THE APEX TIMES
A Yahoo Finance roundup of a r/ValueInvesting bull thesis argues for Pfizer, but the public post offers limited, non-primary detail on the company’s near-term fundamentals.
THE APEX TIMES
A fresh market commentary on Eli Lilly stock centers on whether recent strength is a durable announcement or just a trading pattern, pointing investors back to how long-term portfolio risk is managed in large pharma.
THE APEX TIMES
The move follows a higher-than-average trading session and growing attention to whether analysts are revising profit forecasts upward for Johnson & Johnson.
